RanReshefMDMSc

PubMed

• 262 citations
  Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
  Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz
  The Lancet. Oncology. 2022-01-01
• 7 citations
  Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
  Kamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, Mei-Jie Zhang, Khalid Bo-Subait
  Blood Advances. 2021-09-22
• 490 citations
  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.
  Andrew C. Harris, Rachel Young, Steven M. Devine, William J. Hogan, Francis Ayuk
  Biology of Blood and Marrow Transplantation. 2016-01-01

Journal Articles

• Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...  
  Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica

Abstracts/Posters

• The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
  Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019